Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RescuiNGkids: Nasal Glucagon in Pediatric T1D
NCT04992312Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2022
- Primary completion
- Nov 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glucagon in type 1 diabetes mellitus (T1D), sponsored by Eli Lilly and Company. Primary endpoint: Treatment-Emergent Adverse Events and Serious Adverse Events. Started Mar 2022; status: completed.
02
Drugs
glucagon
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04992312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04992312.